


ABSTRACT OF THE DISCLOSURE

SA

Compounds of formula (I):

99 1576

T10X



PS H

H

H

13

wherein: R¹ is hydrogen, alkyl, halogen, haloalkyl, hydroxy, alkoxy, haloalkoxy, alkylthio, haloalkylthio, amino, alkanoyl, haloalkanoyl, carboxy, alkoxy carbonyl, carbamoyl, cyano, nitro, alkanesulfonyl, haloalkane-sulfonyl or sulfamoyl; R² is optionally substituted alkanoyl, optionally substituted alkenoyl, optionally substituted cycloalkylcarbonyl, substituted benzoyl, or 5,6-dihydro-1,4,2-dioxazin-3-yl; R³ is hydrogen, hydroxy, optionally substituted alkoxy, aralkyloxy, alkanoyloxy, alkenoyloxy, cycloalkylcarbonyloxy, aryl-carbonyloxy, alkoxy carbonyloxy, aralkyloxycarbonylxy, phthalidylxy, (5-methyl-2-oxo-1,3-dioxolen-4-yl)-methoxy, (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy, optionally substituted amino or nitro; Y is -NH- or oxygen or sulfur; n is 1 to 5; and tautomers and salts of said compounds of formula (I), have the ability to inhibit blood platelet aggregation, and can thus be used for treatment and prophylaxis of thrombosis and embolisms.